2. Search Result
Search Result
Results for "

NBI

" in MedChemExpress (MCE) Product Catalog:

42

Inhibitors & Agonists

2

Biochemical Assay Reagents

2

Peptides

1

Inhibitory Antibodies

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-16771
    Valbenazine
    4 Publications Verification

    NBI-98854

    		 Monoamine Transporter Neurological Disease
    Valbenazine (NBI-98854) is a vesicular monoamine transporter 2 (VMAT2) inhibitor with the Ki of 110-190 nM .
    Valbenazine
  • HY-115864
    Osavampator

    TAK-653; NBI-1065845

    		 iGluR Lipoxygenase Neurological Disease
    Osavampator (TAK-653) is a AMPA receptor positive allosteric modulator. Osavampator selectively binds to AMPA-R in a glutamate-dependent manner and induces Ca2+ influx in hGluA1i CHO cells (EC50 = 3.3 μM). Osavampator improves learning and memory in many models. Osavampator is can be used for the research of depressive disorders .
    Osavampator
  • HY-147423
    Zandatrigine
    1 Publications Verification

    NBI-921352; XEN901

    		 Sodium Channel Neurological Disease
    Zandatrigine (NBI-921352; XEN901) is a selective, orally active, voltage-gated sodium channel NaV1.6/SCN8A inhibitor that can penetrate the blood-brain barrier. Zandatrigine inhibits sodium influx by non-covalently binding to the VSD4 structure of NaV1.6, blocking the persistent and resuscitative currents under pathological conditions. Zandatrigine can reduce neuronal hyperexcitability and reduce epileptic seizures. Zandatrigine is 134-756-fold selective for other isoforms such as NaV1.1 and NaV1.2, and has minimal effect on NaV1.1 expressed by inhibitory interneurons. Zandatrigine can be used to study NaV1.6-mediated neuroexcitability diseases such as SCN8A-related developmental epileptic encephalopathy (SCN8A-DEE) and adult focal epilepsy .
    Zandatrigine
  • HY-14369
    Elagolix sodium

    NBI-56418 sodium

    		 GnRH Receptor Nuclear Factor of activated T Cells (NFAT) Metabolic Disease Cancer
    Elagolix sodium is a highly effective, selective, oral-active, short-term, non-peptide gonadotropin-releasing hormone receptor (GnRH receptor) antagonist (KD = 54 pM) and NFAT inhibitor, which can be used to study pain related to endometriosis. .
    Elagolix sodium
  • HY-110135
    NBI-31772
    3 Publications Verification

    		 IGF-1R Neurological Disease Inflammation/Immunology
    NBI-31772 is a non-selective IGFBP inhibitor (Ki=47 nM). NBI-31772 has neuroprotective effects and reduces infarct volume during cerebral ischemia. NBI-31772 can also restore or enhance proteoglycan synthesis in osteoarticular chondrocytes. In addition, NBI-31772 also increases the effect of IGF3 on zebrafish oocyte maturation .
    NBI-31772
  • HY-112085
    N-Bis(2-hydroxypropyl)nitrosamine
    1 Publications Verification

    Di(2-hydroxypropyl)nitrosamine; Diisopropanolnitrosamine

    		 Drug Metabolite Cancer
    N-Bis(2-hydroxypropyl)nitrosamine is a tumor model inducing agent and a metabolite of di-n-propylnitrosamine (DPN). N-Bis(2-hydroxypropyl)nitrosamine can be used to construct pancreatic cancer .
    N-Bis(2-hydroxypropyl)nitrosamine
  • HY-14789
    (R)-Elagolix

    NBI-56418

    		 GnRH Receptor Nuclear Factor of activated T Cells (NFAT) Endocrinology Cancer
    Elagolix is a highly effective, selective, oral-active, short-term, non-peptide gonadotropin-releasing hormone receptor (GnRH receptor) antagonist (KD = 54 pM) and NFAT inhibitor, which can be used to study pain related to endometriosis. .
    (R)-Elagolix
  • HY-15320
    NBI-74330
    Maximum Cited Publications
    9 Publications Verification

    		 CXCR Inflammation/Immunology Endocrinology
    NBI-74330 is a potent antagonist for CXCR3, and exhibits potent inhibition of ( 125I)CXCL10 and ( 125I)CXCL11 specific binding with Ki of 1.5 and 3.2 nM, respectively.
    NBI-74330
  • HY-15793
    NBI-98782
    1 Publications Verification

    (+)-DTBZ; (+)-α-Dihydrotetrabenazine; (+)-α-DHTBZ

    		 Monoamine Transporter Neurological Disease
    NBI-98782 is a high affinity and selectivity vesicular monoamine transporter 2 (VMAT2) inhibitor with a Ki of 3 nM. NBI-98782 has antipsychotic activity .
    NBI-98782
  • HY-14127
    R121919
    5+ Cited Publications

    NBI30775

    		 CRFR Neurological Disease Endocrinology
    R121919 (NBI30775) is a potent and selective CRF1R antagonist with a Ki of 2 to 5 nM. R121919 has antidepressant and anxiolytic effects. R121919 alleviates defensive withdrawal in rats .
    R121919
  • HY-135542
    NBI-27914
    2 Publications Verification

    		 CRFR Others
    NBI-27914 is a highly selective, high-affinity non-peptide competitive antagonist of human corticotropin-releasing factor receptor 1 (CRFR1). NBI-27914 primarily binds to the His199 and Met276 sites in the transmembrane domain of the receptor .
    NBI-27914
  • HY-132228
    Zelatriazin

    TAK-041; NBI-1065846

    		 GPR139 Neurological Disease
    Zelatriazin (TAK-041; NBI-1065846) is a potent and selective GPR139 agonist with an EC50 of 22 nM. Zelatriazin has the potential for the research of negative symptoms associated with schizophrenia .
    Zelatriazin
  • HY-159829
    Direclidine

    NBI-1117568; HTL-0016878

    		 mAChR Neurological Disease
    Direclidine (NBI-1117568, HTL-0016878) is a selective orthosteric agonist targeting the muscarinic acetylcholine M4 receptor, exhibiting very low affinity for M1, M2, M3, and M5 receptors. It binds to the orthosteric site of the M4 receptor in a non-covalent, competitive manner. Direclidine specifically activates the M4 receptor, inhibiting the release of acetylcholine from striatal cholinergic interneurons, thereby regulating the balance of the dopaminergic system and reducing psychiatric symptoms associated with excessive dopamine release. Direclidine can improve symptoms associated with neuropsychiatric disorders and is used in research on schizophrenia and other neuropsychiatric disorders .
    Direclidine
  • HY-156437
    NBI-961

    		Apoptosis Ser/Thr Protease NEKs Mitosis Cancer
    NBI-961 is a potent NEK2 inhibitor that inhibits proteasomal degradation. NBI-961 induces G2/mitosis arrest and apoptosis in diffuse large B cell lymphoma (DLBCL) cells .
    NBI-961
  • HY-W035520
    HBED dihydrochloride

    		Biochemical Assay Reagents Others
    HBED dihydrochloride is an orally active and hexadentate phenolic aminocarboxylate iron chelator. HBED refers to N, N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid, inducing iron excretion in primates. HBED dihydrochloride has the potential to be used as an alternative to desferriamine for iron chelation therapy .
    HBED dihydrochloride
  • HY-110135A
    NBI-31772 hydrate
    3 Publications Verification

    		 IGF-1R Neurological Disease
    NBI-31772 hydrate is a potent inhibitor of interaction between insulin-like growth factor (IGF) and IGF-binding proteins (IGFBPs). NBI-31772 hydrate is also a nonpeptide ligand that releases bioactive IGF-I from the IGF-I/IGFBP-3 complex (Kis=1-24 nM for all six human subtypes). Anxiolytic and antidepressant-like effects .
    NBI-31772 hydrate
  • HY-16771A
    Valbenazine tosylate
    4 Publications Verification

    NBI-98854 tosylate

    		 Monoamine Transporter Neurological Disease
    Valbenazine tosylate (NBI-98854 tosylate) is a vesicular monoamine transporter 2 (VMAT2) inhibitor with the Ki of 110-190 nM .
    Valbenazine tosylate
  • HY-13699
    NBI-42902

    		GnRH Receptor PERK Others
    NBI-42902 is an orally active, potent functional and competitive antagonist of GnRH receptor with an IC50 value of 0.79 nM, a Ki value of 0.56 nM, respectively. NBI-42902 inhibits GnRH-stimulated inositol phosphate (IP) accumulation, Ca 2+ flux, and ERK1/2 activation. NBI-42902 inhibits serum luteinizing hormone (LH) in castrated male macaques. NBI-42902 can be used for research on sex-hormone-related diseases .
    NBI-42902
  • HY-110099
    (±)-NBI-74330

    		CXCR Inflammation/Immunology
    (±)-NBI-74330 is a potent and selective CXCR3 antagonist. (±)-NBI-74330 not only reduces tactile and thermal hypersensitivity but also enhances the analgesic properties of morphine. (±)-NBI-74330 can reduce microglial cell activation, increase astroglial cell activation, and downregulate the expression of some CXCR3 ligands in a rat neuropathic pain model .
    (±)-NBI-74330
  • HY-103378
    NBI 35965 methanesulfonate

    		CRFR Neurological Disease
    NBI 35965 methanesulfonate is a selective, orally active and brain-penetrant corticotropin-releasing factor receptor 1 (CRF1) antagonist with a Ki value of 4 nM and a pKi value of 8.5. NBI 35965 methanesulfonate does not inhibit CRF2. NBI 35965 methanesulfonate reduces CRF or stress-induced adrenocorticotropic hormone (ACTH) production in vivo with pIC50 values of 7.1 and 6.9, respectively. NBI 35965 methanesulfonate shows anxiolytic effects .
    NBI 35965 methanesulfonate
  • HY-121713
    Aniline mustard

    N,N-Bis(2-chloroethyl)aniline

    		 Apoptosis Mitochondrial Metabolism Caspase DNA/RNA Synthesis PARP Reactive Oxygen Species (ROS) Cancer
    Aniline mustard (N, n-BIS (2-chloroethyl) aniline) is an anticancer agent .
    Aniline mustard
  • HY-14145
    NBI-75043

    		Histamine Receptor Others
    NBI-75043 is an antagonist of H1 receptor .
    NBI-75043
  • HY-14128
    NBI-34041

    SB-723620

    		 CRFR Neurological Disease
    NBI-34041 (SB-723620) is a selective and orally active nonpeptide CRF1 receptor antagonist with an IC50 of 58.9 nM and a Ki of 4.0 nM for human CRF1 receptor. NBI-34041 has no inhibitory effect on the CRF2 receptor. NBI-34041 can be used for depression and anxiety disorders research.
    NBI-34041
  • HY-103376
    NBI-27914 hydrochloride

    		CRFR Neurological Disease
    NBI-27914 (hydrochloride) is a selective Corticotropin-Releasing Factor 1 (CRF1) receptor antagonist with a Ki value of 1.7 nM .
    NBI-27914 hydrochloride
  • HY-110135R
    NBI-31772 (Standard)

    		IGF-1R Neurological Disease Inflammation/Immunology
    NBI-31772 (Standard) is the analytical standard of NBI-31772. This product is intended for research and analytical applications. NBI-31772 is a non-selective IGFBP inhibitor (Ki=47 nM). NBI-31772 has neuroprotective effects and reduces infarct volume during cerebral ischemia. NBI-31772 can also restore or enhance proteoglycan synthesis in osteoarticular chondrocytes. In addition, NBI-31772 also increases the effect of IGF3 on zebrafish oocyte maturation .
    NBI-31772 (Standard)
  • HY-162872
    NBI-35965

    		CRFR Neurological Disease
    NBI-35965 is an antagonist of corticotropin-releasing factor receptor 1 (CRF-R1). NBI-35965 can be used in nervous system related research .
    NBI-35965
  • HY-135542R
    NBI-27914 (Standard)

    		CRFR Reference Standards Others
    NBI-27914 (Standard) is the analytical standard of NBI-27914 (HY-135542). This product is intended for research and analytical applications. NBI-27914 is a highly selective, high-affinity non-peptide competitive antagonist of human corticotropin-releasing factor receptor 1 (CRFR1). NBI-27914 primarily binds to the His199 and Met276 sites in the transmembrane domain of the receptor.
    NBI-27914 (Standard)
  • HY-110056
    NBI 35965 hydrochloride

    		CRFR Neurological Disease
    NBI 35965 hydrochloride is a selective, orally active and brain-penetrant corticotropin-releasing factor receptor 1 (CRF1) antagonist with a Ki value of 4 nM and a pKi value of 8.5. NBI 35965 hydrochloride does not inhibit CRF2. NBI 35965 hydrochloride reduces CRF or stress-induced adrenocorticotropic hormone (ACTH) production in vivo with pIC50 values of 7.1 and 6.9, respectively. NBI 35965 hydrochloride shows anxiolytic effects .
    NBI 35965 hydrochloride
  • HY-106171
    NBI-6024

    		Insulin Receptor Metabolic Disease
    NBI-6024, an altered peptide ligand (APL), is an epitope recognized by inflammatory interferon-gamma-producing T helper lymphocytes in type 1 diabetic patients .
    NBI-6024
  • HY-16771R
    Valbenazine (Standard)

    NBI-98854 (Standard)

    		 Monoamine Transporter Reference Standards Neurological Disease
    Valbenazine (Standard) is the analytical standard of Valbenazine. This product is intended for research and analytical applications. Valbenazine (NBI-98854) is a vesicular monoamine transporter 2 (VMAT2) inhibitor with the Ki of 110-190 nM .
    Valbenazine (Standard)
  • HY-16771B
    Valbenazine dihydrochloride

    NBI-98854 dihydrochloride

    		 Dopamine Receptor Neurological Disease
    Valbenazine (NBI-98854) dihydrochloride is a VMAT2 inhibitor, used to treat tardive dyskinesia. Valbenazine dihydrochloride demonstrates potential benefit in alleviating symptoms associated with movement disorders resulting from chronic dopamine receptor blocking medications. Valbenazine dihydrochloride has been supported by evidence from preclinical models examining its role in the genetic factors linked to tardive dyskinesia.
    Valbenazine dihydrochloride
  • HY-W751574
    Elagolix-d6 sodium

    NBI-56418-d6 sodium

    		 Isotope-Labeled Compounds Nuclear Factor of activated T Cells (NFAT) GnRH Receptor Endocrinology Cancer
    Elagolix-d6 (sodium) (NBI-56418-d6 (sodium)) is deuterium labeled Elagolix sodium. Elagolix sodium is a highly effective, selective, oral-active, short-term, non-peptide gonadotropin-releasing hormone receptor (GnRH receptor) antagonist (KD = 54 pM) and NFAT inhibitor, which can be used to study pain related to endometriosis. .
    Elagolix-d6 sodium
  • HY-115645
    R121919 hydrochloride

    NBI30775 hydrochloride

    		 CRFR Neurological Disease Metabolic Disease
    R121919 (NBI30775) hydrochloride is a potent and selective CRF1R antagonist with a Ki of 2 to 5 nM. R121919 hydrochloride has antidepressant and anxiolytic effects. R121919 hydrochloride alleviates defensive withdrawal in rats .
    R121919 hydrochloride
  • HY-14127R
    R121919 (Standard)

    NBI30775 (Standard)

    		 CRFR Reference Standards Neurological Disease Endocrinology
    R121919 (Standard) is the analytical standard of R121919. This product is intended for research and analytical applications. R121919 (NBI30775) is a potent and selective CRF1R antagonist with a Ki of 2 to 5 nM. R121919 has antidepressant and anxiolytic effects. R121919 alleviates defensive withdrawal in rats .
    R121919 (Standard)
  • HY-112085R
    N-Bis(2-hydroxypropyl)nitrosamine (Standard)

    Di(2-hydroxypropyl)nitrosamine (Standard); Diisopropanolnitrosamine (Standard)

    		 Others Reference Standards Cancer
    N-Bis(2-hydroxypropyl)nitrosamine (Standard) is the analytical standard of N-Bis(2-hydroxypropyl)nitrosamine. This product is intended for research and analytical applications. N-Bis(2-hydroxypropyl)nitrosamine is a tumor model inducing agent and a metabolite of di-n-propylnitrosamine (DPN). N-Bis(2-hydroxypropyl)nitrosamine can be used to construct pancreatic cancer .
    N-Bis(2-hydroxypropyl)nitrosamine (Standard)
  • HY-14369R
    Elagolix sodium (Standard)

    NBI-56418 sodium (Standard)

    		 Reference Standards GnRH Receptor Endocrinology Cancer
    Elagolix sodium (Standard) is the analytical standard of Elagolix sodium. This product is intended for research and analytical applications. Elagolix sodium is a human GnRH receptor (GnRHR) antagonist with an IC50 and Ki of 0.25 and 3.7 nM, respectively.
    Elagolix sodium (Standard)
  • HY-14789R
    (R)-Elagolix (Standard)

    NBI-56418 (Standard)

    		 GnRH Receptor Nuclear Factor of activated T Cells (NFAT) Reference Standards Endocrinology Cancer
    (R)-Elagolix (Standard) is the analytical standard of (R)-Elagolix. This product is intended for research and analytical applications. Elagolix is a highly effective, selective, oral-active, short-term, non-peptide gonadotropin-releasing hormone receptor (GnRH receptor) antagonist (KD = 54 pM) and NFAT inhibitor, which can be used to study pain related to endometriosis. .
    (R)-Elagolix (Standard)
  • HY-P990708
    Bizaxofusp

    MDNA55; NBI-3001; PRX-321

    		 Interleukin Related Apoptosis Inflammation/Immunology Cancer
    Bizaxofusp (MDNA55) is a fusion protein formed by the linkage of IL-4 and a truncated Pseudomonas exotoxin. Bizaxofusp can bind to IL-4 receptors on the surface of tumor cells and be internalized, and its exotoxin moiety can inhibit protein synthesis and induce tumor cell apoptosis. Bizaxofusp can be used in the study of cancer .
    Bizaxofusp
  • HY-W129500
    N-[[Bis[4-(dimethylamino)phenyl]amino]carbonyl]glycine sodium

    		Biochemical Assay Reagents Others
    N-[[Bis[4-(dimethylamino)phenyl]amino]carbonyl]glycine sodium can be used as a biomonitoring reagent to measure redox activity through a colorimetric reaction.
    N-[[Bis[4-(dimethylamino)phenyl]amino]carbonyl]glycine sodium
  • HY-14369S
    Elagolix-13C,d3 sodium

    NBI-56418-13C,d3 sodium

    		 Isotope-Labeled Compounds GnRH Receptor Endocrinology Cancer
    Elagolix- 13C,d3 (sodium) is the 13C- and deuterium labeled Elagolix sodium. Elagolix sodium is a human GnRH receptor (GnRHR) antagonist with an IC50 and Ki of 0.25 and 3.7 nM, respectively.
    Elagolix-13C,d3 sodium
  • HY-119247
    NBI 30545

    		CRFR Neurological Disease
    NBI 30545 is a blood-brain barrier permeable CRF1R antagonist with a Ki value of 3.4 nM for the human receptor. NBI 30545 inhibits CRF-stimulated intracellular cAMP accumulation and ACTH release. NBI 30545 can be used in the research of depression, anxiety disorders and stress-related diseases .
    NBI 30545
  • HY-W075595
    (2S,2'S)-2,2'-(1,3,8,10-Tetraoxo-1,3,8,10-tetrahydroanthra[2,1,9-def:6,5,10-d'e'f']diisoquinoline-2,9-diyl)dipropionic acid

    N, N'-bis (L-alanine) perylene diamide

    		 MOFs Others
    (2S,2'S)-2,2'-(1,3,8,10-Tetraoxo-1,3,8,10-tetrahydroanthra[2,1,9-def:6,5,10-d'e'f']diisoquinoline-2,9-diyl)dipropionic acid (N, N'-bis (L-alanine) perylene diamide) is a metal-organic framework (MOF).
    (2S,2'S)-2,2'-(1,3,8,10-Tetraoxo-1,3,8,10-tetrahydroanthra[2,1,9-def:6,5,10-d'e'f']diisoquinoline-2,9-diyl)dipropionic acid

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: